Drug Profile
Research programme: pepetidomemtic therapeutics - Fimbrion therapeutics
Latest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Fimbrion Therapeutics
- Class Peptidomimetics; Small molecules
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Urinary tract infections
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for research development in Urinary-tract-infections in USA (PO)
- 27 Oct 2016 Early research in Urinary tract infections in USA (PO)